INTRODUCTION
The relationship between GH hypersecretion and carbohydrate metabolism is complex and not completely understood. There is a high prevalence of impaired glucose tolerance (35-50%) and overt diabetes mellitus (9-23%) in patients with active acromegaly, mainly due to insulin resistance (IR) (1-3). Somatostatin analogs therapy is today the medical treatment of choice for acromegaly. It has divergent effects on glucose metabolism, depending on inhibition of GH and glucagon secretion, which may improve insulin action, and on suppression of insulin release itself. Results of previous studies on octreotide administration with daily multiple injections showed an improvement in whole body insulin sensitivity with variable effects on glucose lev-Key-words: Octreotide, lanreotide, glucose metabolism, insulin resistance, IGF-I. 502 treatment (p<0.05 vs baseline and L-SR). Mean HOMA-IR values calculated in acromegalic patients before medical therapy were higher than in normal subjects (p<0.005) and showed a significant decrease during both treatments (p<0.05). In the 2 diabetic acromegalic patients a worsening in glucose metabolism was observed during O-LAR treatment but not during L-SR. GH and IGF-Ilevels significantly decreased with both drugs and normalized respectively in 38% and 12% with L-SR, 50% and 25% with O-LAR. In conclusion, both drugs decreased IR in acromegalic patients; O-LAR seems to be more detrimental to glucose metabolism than L-SR, despite being more effective in reducing GH and IGF-Ilevels.
(J. Endocrinol. Invest. 25: 502-507,2002) ©2002, Editrice Kurtis els. Different effects have been reported in diabetic acromegalic patients (4-7). Recently 2 new long acting release formulations of somatostatin analogs have been developed, lanreotide-slow release (L-SR) and octreotide-Iong acting release (O-LAR), Both drugs have been shown to be effective in lowering GH and IGF-I (8-13) and offer a considerable improvement in compliance of acromegalic patients, as the drugs need to be administered im every 7-14 days (L-SR) or every 28 days (O-LAR), respectively, Studies comparing the 2 formulations seem to suggest that O-LAR is more effective than L-SR in the treatment of acromegaly (14-18). Not enough information is available about the effects of the 2 drugs on glucose control. had microadenoma. Mean duration of acromegaly from time of diagnosis was 76±48 months (range 24-180). Eight of 10 patients underwent unsuccessful pituitary surgery followed by pituitary irradiation (conventional extemal irradiation in 3 and gamma-knife in 2 patients) in 5, from 1 to 5 yr (median: 3 yr) before the beginning of the study. Before medical therapy, mean GH levels were 1 0±5 ~g/I (range 5.2-19) and mean IGF-Ilevels were 99±43 nmol/I (range 64-190). One patient was also hyperprolactinemic, but did not receive dopaminergic treatment before and during the study. No deficiencies of anteropituitary hormones were found. Two patients had Type 2 diabetes mellitus (DM), according to the American Diabetes Association criteria (19), diagnosed before the start of the study. One patient was treated with oral antidiabetic drugs and the other with both oral antidiabetic drugs and insulin. Eighteen sex-and age-matched healthy subjects, recruited among medical staff (mean BMI 25±4 kg/m2, range 20.1-30), were studied as normal controls for the evaluation of IR. The local Ethical Committee had approved the protocol study, and all the patients gave their informed written consent to participate in this study.
MATERIALS AND METHODS

Patients
Treatment protocol
All patients received L-SR for a mean period of 19±16 months (range 6-60) as first treatment. The starting schedule of 30 mg im injection every 14 days was adjusted according to GH/IGF-I values, by shortening the interval between drug administration to 10 or 7 days. After a 3-month washout period, all patients received O-LAR 20 mg im every 28 days for a mean period of 21 ± 10 months (range 6-36). The dose was increased or decreased on the base of the GH/IGF-I levels of each patient. Fasting serum GH (mean of at least 5 samples obtained during 2 h saline infusion) and serum IGF-I levels were evaluated at baseline and at the end of the treatment period with the given somatostatin analogs, on the same day andjust before drug injection. Carbohydrate metabolism was checked in all patients by fasting glucose and insulin levels, glycosylated hemoglobin (HbA1c) levels, IR evaluated by the homeostatic model assessment (HOMA-IR each patient according to the following scale: 0: absent; 1: improved; 2: unchanged; 3: worsened. Main biochemical and hematological evaluations, like liver and kidney function parameters, blood counts, coagulation factors, and lipid metabolism parameters, were evaluated at baseline and during medical therapy. Ultrasound scans of the gall bladder were also periodically performed.
